A Three Part, First-in-human, Randomized, Double-masked, Placebo-Controlled, Safety, Tolerability and Early Efficacy Study of MGV354 in Healthy Subjects and in Patients With Ocular Hypertension or Glaucoma

Trial Profile

A Three Part, First-in-human, Randomized, Double-masked, Placebo-Controlled, Safety, Tolerability and Early Efficacy Study of MGV354 in Healthy Subjects and in Patients With Ocular Hypertension or Glaucoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs MGV 354 (Primary)
  • Indications Open-angle glaucoma
  • Focus First in man; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 27 Sep 2016 Status changed from recruiting to completed.
    • 15 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
    • 15 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top